Malteser Norddeutschland gGmbH
- Address
- Waldstrasse 17, Westliche Hoehe, 24939 Flensburg, Germany
Malteser Norddeutschland gGmbH - Hematologic Malignancies and Oncology Research Center
Malteser Norddeutschland gGmbH is a specialized clinical research center with extensive expertise in hematologic malignancies and solid tumor oncology. The center demonstrates particular strength in evaluating novel therapeutic combinations and targeted therapies for blood cancers, with a strong emphasis on precision medicine approaches guided by genetic markers and molecular profiling.
- Acute Myeloid Leukemia (AML) - investigating targeted therapies for IDH1/IDH2 mutations, FLT3 mutations, and NPM1-mutated disease in both intensive and non-intensive treatment settings
- Multiple Myeloma - comprehensive research program including induction therapy combinations, post-transplant maintenance strategies, and minimal residual disease assessment
- Hodgkin Lymphoma and Colorectal Cancer - advanced stage treatment optimization and adjuvant therapy strategies
- Non-Small Cell Lung Cancer - targeted therapies for KRAS G12C mutations in combination with immunotherapy
The center's research portfolio reflects a commitment to improving patient outcomes through innovative combination therapies and biomarker-driven treatment selection. Their participation in multinational phase III trials demonstrates capabilities in evaluating both novel agents and optimized treatment regimens, with particular focus on reducing treatment-related toxicity while maintaining or improving efficacy through personalized therapeutic approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Malteser Norddeutschland gGmbH
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung cancer with poor performance status (SPACE-T) [without IMPD-Q] | AIO-Studien gGmbH | Phase II | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 3 | Unknown | 2016-07-15 | 2024-04-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.